Investor presentation to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer
Genprex's President and CEO, Rodney Varner, sits down with CEO/CFO Magazine to talk about Genprex, how it is reprogramming the course of cancer and diabetes and key catalysts in the next 6-12 months.
Investor presentations to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer
Amendment to existing worldwide, exclusive license agreement expands Genprex’s oncology franchise
Company achieves another milestone relating to its clinical trial strategy
Acclaim-2 Clinical Trial Combines REQORSA™ immunogene therapy with Merck & Co’s Keytruda®
Designed and Secured by Barsec